Review ArticleSacituzumab Govitecan-hziy in Breast CancerKwapisz, Dorota MD Author Information University Clinical Center of the Medical University of Warsaw, Warsaw, Poland D.K. contributed in conception and design/idea for the article, acquisition of data/literature search, analysis and interpretation of data, wrote the paper, critically revised the work, approval of the final version of the manuscript. The author declares no conflicts of interest. Correspondence: Dorota Kwapisz, MD, University Clinical Center of the Medical University of Warsaw, 02-005, Warsaw, Poland. E-mail: [email protected]. American Journal of Clinical Oncology: July 2022 - Volume 45 - Issue 7 - p 279-285 doi: 10.1097/COC.0000000000000919 Buy Metrics Abstract Trophoblast cell-surface antigen-2 (Trop-2) is a transmembrane calcium signal transducer and its overexpression is common in many types of malignant epithelial tumors, including breast cancer (BC). Sacituzumab govitecan-hziy (SG), the anti-Trop-2 antibody-drug conjugate, resulted in a significant survival benefit over chemotherapy in patients with metastatic triple-negative breast cancer (mTNBC). The greatest efficacy was observed in those who had a medium or high Trop-2 score. However, the importance of Trop-2 as a potential predictive factor requires further research. Elderly patients also appear to benefit from treating with SG. While the early results are encouraging, the ultimate benefit of SG in patients with brain metastases has yet to be determined. Early phase studies have shown that SG is also active in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic BC. The most common side effects of SG are nausea, neutropenia and diarrhea. Currently, several clinical trials are in progress with SG in monotherapy and in combination treatment for various types of BC. Taken together, SG should be considered as a new standard of care in patients with pretreated mTNBC. This review summarizes the development and highlights recent advances of the SG in BC. Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.